
Masayuki Iki, Yuuki Fujita, Junko Tamaki, Katsuyasu Kouda, Akiko Yura, Eiko Kadowaki, Yuho Sato, Jong-Seong Moon, Nozomi Okamoto, and Norio Kurumatani for Fujiwara-kyo Study Group

1 Department of Public Health, Kinki University School of Medicine, 377-2 Oono-higashi, Osaka-Sayama, Osaka 589-8511, Japan
2 Department of Human Life, Jin-ai University, 3-1-1 Ootemachi, Echizen, Fukui 915-8586, Japan
3 Faculty of Human Sciences, Taisei Gakuin University, 1030-1 Hirao, Mihara-ku, Sakai, Osaka 587-8555, Japan
4 Department of Community Health and Epidemiology, Nara Medical University School of Medicine, 840 Shijocho, Kashihara, Nara 634-8521, Japan

§ Corresponding author

Email addresses:
MI: masa@med.kindai.ac.jp
YF: yfujita@med.kindai.ac.jp
JT: jtamaki@med.kindai.ac.jp
KK: kouda@med.kindai.ac.jp
AY: ayuko@med.kindai.ac.jp
EK: eiko@med.kindai.ac.jp
YS: y-sato@jindai.ac.jp
JSM: mjs@tgu.ac.jp
NO: onozomi@nmu-gw.naramed-u.ac.jp
NK: knorio@nmu-gw.cc.naramed-u.ac.jp
Abstract

Background
Osteoporosis and osteoporotic fracture in men are significant public health problems in an aging society. However, information on male osteoporosis remains impressively lacking, especially for Asians. We designed the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) study as an ancillary study of a cohort study, the Fujiwara-kyo study, to determine risk factors for osteoporotic fractures in Japanese men.

Methods

Design: A prospective cohort study with at least a 5-year follow-up
Setting: A population-based single centre study
Subjects: All the male participants of the Fujiwara-kyo study who were living in the four cities studied, aged 65 years and older, and able to walk without aid from others.
Primary outcome: Incidence of osteoporotic fractures including vertebral and clinical non-vertebral fractures.
Additional outcomes: Change in bone mineral density (BMD), change in hip geometry, onset of receiving benefits from Long-term Care Insurance (LCI), health-related quality of life, and mortality.
Baseline measurements: BMD at the lumbar spine (LS) and hip (TH), hip geometry, vertebral deformity assessment, bone turnover markers, physical and cognitive performance, various medical and lifestyle factors, and geriatric psychosocial measures confirmed by interviews based on self-administrated questionnaires.
Outcome surveillance: Annual mail surveys and a follow-up survey at the fifth year comprising similar items to the baseline study will be used to determine the outcomes. Receipt of benefits from LCI and mortality will be obtained from the city governments.

Results
The baseline study was conducted for 2174 eligible men, and 2012 completed the study and were eligible for follow-up. Prevalence rates of osteoporosis (BMD 2.5 SD or more below the young adult mean (YAM)) and low BMD (BMD 1 SD or more below YAM) in at least one of LS and TH were calculated to be 4.4% and 41.8%, respectively. The proportion of men with low BMD only at TH showed a significant increasing trend with
aging (p<0.0001) while that only at LS showed a decreasing trend (p=0.0386). The
prevalence rate of osteoporosis was underestimated when diagnosed using only BMD at
LS. Other baseline measurements were successfully obtained.

Conclusions
FORMEN baseline study was performed as designed and the FORMEN cohort study
was successfully launched.
Background

Osteoporotic fracture is a significant and increasing public health burden, for men as well as women, in aging societies. The lifetime risk for osteoporotic fracture was estimated to be 40% in women and 13% in men [1]. These figures, however, may be underestimated by nearly half, and have been suggested to be as high as 23% in men when taking future reduction of mortality into account [2]. The incidence of hip fracture, the most serious osteoporotic fracture, is increasing. The number of hip fractures is projected to be 13 million in 2050, with 31% of these (approximately 4 million), occurring in men [3]. It has been well established that the incidence rate of hip fracture is much higher in Caucasians than in Asians [4], but Asians will account for 45% of hip fractures globally in 2050 because the population of elderly people in Asia is increasing dramatically [3]. In Japan, nation-wide surveys for the incidence of hip fracture have been conducted four times since 1987 [5]. There were 117,900 incident hip fractures estimated in 2002, double the number from 1987, of which 22% occurred in men [6]. This trend in the incidence of osteoporotic fractures urges us to establish a comprehensive strategy to prevent and manage osteoporosis in men as a national and international issue with the highest priority.

In spite of the magnitude of the problem posed by osteoporosis in men, there remains a substantial shortage of information concerning male osteoporosis, especially in Asia. Only a few prospective cohort studies have been performed for the determinants of osteoporotic fracture in Hong Kong Chinese men [7] and in Japanese men [8, 9, 10]. Some of these have been well performed with a sufficiently high follow-up rate, but the sample size did not exceed 800, which was not sufficiently large for evaluating determinants of osteoporotic fractures [8-10]. Furthermore, comprehensive geriatric assessments for the evaluation of risk factors for osteoporotic fracture are lacking. Without these data, it would be difficult to design rational clinical and preventive approaches for osteoporosis and osteoporotic fracture in men. Thus, we have designed and launched the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study, a large-scale community-based single-centre prospective cohort study for elderly Japanese men, to address the following questions:
1. Does bone mass predict fracture risk in men as has previously been demonstrated in women?
2. Which lifestyle or medical factors are associated with fracture risk in men?
3. Do physical performance test results predict fracture risk in men?
4. Do bone turnover markers enhance the predictive value of bone density and other clinical risk factors for fracture risk in men?
5. Does socioeconomic status affect the risk of osteoporosis and osteoporotic fracture in men?
6. To what extent do fractures in men increase the risk of being dependent on care provided from Long-term Care Insurance (LCI)?
7. To what extent do fractures affect quality of life (QOL) in men?
8. Do existing vertebral fractures and incident non-vertebral fractures increase risk of death in men?

We present in this paper the design of the FORMEN study and the baseline characteristics of its participants.

**Methods**

1. **General study description**

   The FORMEN study is an ancillary study of a larger prospective cohort study, The Cohort Study for Functioning and Quality of Life in Elderly Japanese (Primary Investigator: Norio Kurumatani, M.D., Ph.D., Professor and Chairman, Department of Community Health and Epidemiology, Nara Medical University School of Medicine), which is referred to as the “Fujiwara-kyo study” after the study area where the first capital of Japan, called “Fujiwara-kyo,” was established in 694 AD. The Fujiwara-kyo study aims to provide a scientific basis for a comprehensive strategy to prevent frailty, increase the number of healthy life years, and promote the functioning and quality of life of the elderly men and women in Japan [11]. The FORMEN study examines male participants of the Fujiwara-kyo study for bone health. Most of the non-skeletal measurements and interviews were conducted under the Fujiwara-kyo study, and these
data form a comprehensive geriatric and gerontologic basis for the FORMEN study to evaluate risk factors of osteoporosis and osteoporotic fracture of elderly men. Brief explanations of the Fujiwara-kyo study appear in this paper and details of the study are described elsewhere. [11]

2. Study population and recruitment of samples

To achieve the aims of the Fujiwara-kyo study, participants in the study should be representative of elderly men and women who are still living independently in a community and can participate in various preventive activities conducted by their municipalities. For the inclusion criteria, therefore, participants should be:

1. aged 65 years or older at baseline,
2. living in their homes in the cities of Kashihara, Nara, Yamato-Kooriyama, and Kashiba, which are surrounding areas of the Nara Medical University Hospital (Figure 1),
3. able to walk without the assistance of another person,
4. able to provide self-reported information, and
5. able to understand and provide written informed consent [11].

The FORMEN study included all the male participants of the Fujiwara-kyo study. The recruitment of participants was conducted by the Administrative Centre of the Fujiwara-kyo study with the cooperation of local residents’ associations and elderly people’s clubs organized in every district of the cities studied. These groups used printed literature that included information on the aims of the study, study procedures, risks and benefits posed by study measurements, rights and responsibilities of participants and researchers, publication of results, and protection of privacy. The participants were asked to give written informed consent before enrolment in the study. The sample sizes necessary for the Fujiwara-kyo study and the FORMEN study were set as 4500 [11] and 2000 as described later, respectively.
3. Outcome indices

The primary outcome for the FORMEN study is the incidence of osteoporotic
fractures, including vertebral fractures and clinical non-vertebral fractures. The
additional outcomes consist of change in bone mineral density (BMD), change in hip
geometry, onset of receiving benefits from LCI, which is an objectively assessed index
of having become physically or cognitively dependent on other people in daily life,
change in QOL, and death.

4. Study measures

A. Skeletal measures

A-1. Bone mass measurement

Bone mineral content (BMC) (g) and bone area (cm\(^2\)) were measured by dual-
energy X-ray absorptiometry (DXA) at the lumbar spine (L2-4) and right hip in a
posteroanterior projection (QDR4500A, Hologic Inc., Bedford, MA, USA) as
previously described [12]. Participants with either a history or incident involvement of
fractures or bone disease in the right hip were scanned on the left side. We excluded
densitometric data of the spine for participants with vertebral fractures or grade four
osteophytes according to Nathan's classification [13], or those with hip deformities in
the regions of interest (ROI), from the analysis. All spine and hip measurements
throughout the study were made with one scanner installed in a mobile test room in a
large vehicle. BMD (g/cm\(^2\)) was obtained by BMC divided by bone area at the lumbar
spine (LS) and total hip (TH). TH was divided into several regions including the
femoral neck (FN) and trochanter (TR). The short-term precision as measured by the
coefficients of variation (CV) of the BMD measurements in vivo was 1.2%, 1.2%, 1.6%
and 1.9% for LS, TH, FN and TR, respectively. Quality assurance of the measurements
was conducted daily before the study measurements began. We observed no remarkable
drift in BMD values for the spine phantom throughout the baseline study period.

We defined osteoporosis as BMD values 2.5 SD or more below the young adult
mean (YAM) [14], and low BMD as 1 SD or more below YAM, in accordance with the
WHO criteria [15].
**A-2. Hip geometric assessment**

The archived DXA image used for calculating BMD at the hip was subsequently analyzed using Apex software’s Hip Structure Analysis (HSA) program (Hologic Inc., Bedford, MA, USA). The precise method has been described elsewhere [16]. The HSA program automatically set three ROIs defined as: (1) narrow neck, traversing the narrowest width of the femoral neck, (2) intertrochanter, along the bisector of the shaft and femoral neck axis, and (3) shaft, at 1.5 times the minimum neck width distal from the intersection of the neck and shaft axes. The HSA program yielded several hip geometric indices including cross-sectional area, cross-sectional moment of inertia, section modulus, cortical thickness and subperiosteal diameter for each of three ROIs.

**A-3. Vertebral deformity assessment**

We imaged the thoracolumbar vertebrae of each participant by single-energy X-ray absorptiometry (SXA) following bone density measurements. Bone morphometric software (QDR4500A Lateral Image Analyze, Hologic Inc., Bedford, MA, USA) was used to measure anterior, central and posterior edge heights of each vertebra using the SXA images. We diagnosed vertebral deformities according to the McCloskey-Kanis criteria [17] and used these as a proxy for vertebral fracture in the baseline study. We visually confirmed all deformed vertebrae according to Genant’s semiquantitative assessment method [18].

**A-4. History of symptomatic fractures**

History of symptomatic fracture was determined by interviewer-confirmed self-reports from participants. When a participant reported a symptomatic fracture having occurred at any time of his life, a trained registered nurse conducted an in-person interview to determine when the injury occurred, which bone or part of body was injured, what activities the participant was engaged in when injured, and whether a physician diagnosed the injury as a fracture according to radiographic examinations. We
defined a symptomatic fracture as one which caused a clinic visit due to pain and was
diagnosed as a fracture by a physician using radiographs.

A-5. Bone turnover markers and other laboratory measures

We drew blood from each participant after an overnight fast and obtained serum
for several conventional biochemical tests planned in the Fujiwara-kyo study. We stored
the remaining serum at -80 °C until we performed measurements for the FORMEN
study. We measured levels of bone turnover markers including osteocalcin (OC),
undercarboxylated OC (ucOC), and tartrate-resistant acid phosphatase isoenzyme 5b
(TRACP-5b). In addition, we will measure Type I collagen cross-linked C-terminal
telopeptide (CTX) and type I procollagen N-terminal propeptide (P1NP). As non-
skeletal markers, we measured serum levels of high-sensitivity CRP and homocysteine.

We measured OC [ng/ml] using a two-site immunoradiometric assay (BGP
IRMA kit Mitsubishi, Mitsubishi Kagaku Iatron Inc., Tokyo, Japan) with a sensitivity of
1 ng/ml [19]. The precision of this measurement was 4.9%, 3.7% and 6.1% for
intraassay CV, interassay CV and overall CV, respectively.

We used an electrochemiluminescence immunoassay to measure ucOC [ng/ml]
(Picolumi ucOC, Sanko Junyaku Co. Ltd., Tokyo, Japan) with a sensitivity of 0.39
ng/ml [20]. The precision of this measurement was 4.1%, 3.5% and 5.4% for intraassay
CV, interassay CV and overall CV, respectively.

TRACP-5b was measured by a fragment-absorbed immunocapture enzyme
assay (Osteolinks-TRAP-5b, Nitto Boseki, Kooriyama, Japan) with a sensitivity of 19.2
mU/dl [21]. The intraassay CV, interassay CV and overall CV of this measurement in
our laboratory were 4.9%, 7.3% and 8.8%, respectively.

Serum levels of CTX and P1NP will be measured using an enzyme-linked
immunoassay (Serum CrossLaps ELISA, Immunodiagnostic Systems Ltd., Boldon,
UK)[22] and a two-site electrochemiluminescence immunoassay (Roche Elecsys 2010,
Roche Diagnostics, Lewes, UK)[23], respectively.
**B. Non-skeletal measures**

Non-skeletal measures were obtained in the Fujiwara-kyo study. Detailed information on the measurements is described elsewhere [11], but we state briefly here some measures relevant to the FORMEN study.

**B-1. Clinical measures**

We measured participant height (cm), weight (kg) and waist circumference (cm), and calculated body mass index (BMI)(kg/m$^2$).

**B-2. Physical and cognitive performance measures**

A series of physical performance tests for elderly people were conducted including muscle grip strength, muscle strength of knee extensors and flexors, brisk gait speed, the timed up-and-go test, and the timed one-leg balance with eyes open. To quantify cognitive function, participants completed the Modified Mini-Mental State Examination [24].

**B-3. Medical history, and gerontological lifestyle and socioeconomic factors**

Participants completed a questionnaire including 250 items covering medical history including thyroid diseases, parathyroid diseases, rheumatoid arthritis, connective tissue diseases, malignant diseases, hypertension, diabetes mellitus, coronary heart diseases, hyperlipidemia, asthma, kidney diseases and prostate diseases, history of medications due to these diseases, several scales of geriatric and gerontological factors, smoking and drinking history, diet history including intake of dairy products and a fermented soy bean product called ‘natto’ in Japanese, physical activity indices necessary for quantification using the International Physical Activity Questionnaire (IPAQ) [25], fall and fracture history, family history of fractures, symptoms in back and joints, level of education, social and economic status, and marital status. Participants were asked to bring current prescriptions of medications to the baseline visit where interviewers recorded the name and dose of the medications. Participants were also asked to complete a seven-day diary of their diets to estimate dietary nutrient intakes.
B-4. Quality of life assessment

Health-related quality of life was assessed with the 36-item short form of the Medical Outcomes Study Questionnaire (SF-36) [26].

5. Outcome surveillance

To obtain outcome indices, annual mail surveys and a follow-up survey in the fifth year comprising similar study items to the baseline study will be conducted as part of the Fujiwara-kyo study. [11]

A. Incident vertebral fractures

An incident vertebral fracture is diagnosed morphometrically based on SXA images of the spine when the anterior, central or posterior height of a vertebra is reduced by 20% or more on follow-up compared to baseline, and when the vertebra also satisfied the McCloskey-Kanis criteria [17]. Vertebrae with heights reduced by 20% or more which do not satisfy the McCloskey-Kanis criteria are considered to be incident fractures if they satisfy the definition of grade 2 or 3 fracture by the Genant method [18].

B. Change in bone density and hip geometry

Bone densitometry will be conducted in the follow-up survey at the same skeletal sites with the same densitometer as used in the baseline study. Changes in BMD at LS, TH, FN and TR, and in hip geometry indices will be determined.

C. Non-vertebral and symptomatic vertebral fractures

When a participant reports on the annual questionnaire the occurrence of fracture in the previous year, a trained nurse will conduct a telephone interview and obtain details of the injury to determine whether the injury is a fracture or not. Reviews of participant medical records will be further conducted with the written permission of the participant.
D. Onset of receiving benefits from LCI and death of participants

We will obtain information regarding whether a participant starts receiving benefits from LCI from response on the annual questionnaire. In the case that a participant dies in the previous year, the family is to inform the Administrative Centre of the Fujiwara-kyo study of the participant's death. When a participant does not respond to the annual questionnaire, the Administrative Centre will contact the city office and obtain the information on the participant’s receipt of benefits and survival. Participants have given the researchers their consent to this inquiry.

6. Statistical analysis

A. Primary analyses

The primary analyses consist of assessments of baseline risk factors for the primary and additional outcomes of the study. The risk factors will be thoroughly investigated from among the skeletal and non-skeletal measures obtained at baseline. To evaluate risk factors for vertebral fractures and clinical non-vertebral fractures, we will conduct logistic regression analysis and Cox proportional hazards regression analysis, respectively. Factors associated with changes in BMD and hip geometry indices will be evaluated by multiple regression analysis. The proportional hazards regression will also be applied to evaluate risk factors for receiving benefits from LCI, and mortality. Determinants for changes in QOL will be evaluated by multiple regression analysis. Additional effects of the incidence of osteoporotic fractures during follow-up on receiving LCI benefits, changes in QOL and survival will be evaluated after adjusting for their potential risk factors at baseline.

B. Additional analyses

Additional analyses, mostly cross-sectional, are being conducted for provisional assessments of known and potential risk factors for the outcome indices. These include the effects of socioeconomic status, medical histories, physical and cognitive performance, and lifestyle factors including smoking, drinking, milk consumption and “natto” intake on BMD, low BMD, and vertebral fractures.
7. Sample size calculations

The sample size necessary for the FORMEN study was set as 2000. This was obtained in order that the logistic regression analysis yields a significant estimate with a two-tailed level of significance at 5% and a statistical power of 80% for a risk factor of fracture which exists in 20% of the population and increases the fracture risk by 75% compared with people without the risk factor who run the absolute fracture risk of 1% per year. The statistical power afforded by the sample size of 2000 under several other assumptions is shown in Table 1.

8. Study timeline

The complete schedule of the Fujiwara-kyo study is illustrated in Figure 2. The study enrolled participants and completed the baseline survey from June 2007 to October 2008. A follow-up survey covering most of the items examined in the baseline survey is scheduled in 2012 after an average follow-up period of 4.5 years. During the interim, the participants are asked to respond to annual mailed questionnaires for the surveillance of the outcome indices of the study. The third annual questionnaire covers more extensive items to update important information obtained at baseline. [11]

9. Study administration

The Administrative Centre of the Fujiwara-kyo study is organized in the Department of Community Health and Epidemiology, Nara Medical University School of Medicine. The Core Member Committee, established as a steering committee of the study, is chaired by the Principal Investigator and composed of core investigators from all the study areas. This committee takes responsibility for designing the primary scope of the study, developing protocols, organizing subcommittees for ancillary studies, setting specific research directions and goals, sharing publication opportunities, and smoothing inter-institutional collaborations. Core investigators are responsible for designing protocols for their specific area of study, conducting the measurements at the surveys, and collecting and collating the data for their areas of responsibility. [11]
The FORMEN Administrative Center is organized in the Department of Public Health, Kinki University School of Medicine, to conduct the FORMEN study smoothly in close cooperation with the Fujiwara-kyo study. The study protocol of the Fujiwara-kyo study was approved by the Medical Ethics Committee of the Nara Medical University, and that of the FORMEN study was approved by the Ethics Committee of the Kinki University School of Medicine.

Results

1. Participant recruitment

During the baseline study period, 2174 men and 2253 women participated in the Fujiwara-kyo study. Among the male participants, 2012 men completed the measurements conducted in the FORMEN study and were eligible for further analyses and the cohort study. The average age of the participants was 73.3±5.3 (mean ± SD) years with a range of 65 to 94 years. They were 162.8±5.7 cm tall, weighed 60.9±8.6 kg, and had a mean BMI of 22.9±2.8.

Table 2 shows comparisons of age distribution and body size parameters between FORMEN study participants and the male population of Nara Prefecture [27,28] or Japan [27, 29]. The FORMEN participants comprised a higher proportion of men aged 70-79 and were slightly taller than the general population of Japan, but were very similar in body size to men in Nara Prefecture.

2. Characteristics of participants

A. Medical history and lifestyle factors

Medical history and lifestyle factors of the study participants are listed in Table 3. The prevalence rate of cerebrovascular diseases and malignant diseases including prostate cancer increased with aging. Lifestyle factors listed in this table were all significantly related to age. With the increase in age, participants drank more milk, smoked less, drank less alcohol and expended less energy. We also obtained
information regarding other lifestyle factors, including dietary intake and exercise history, which will be presented in future publications.

B. Skeletal measures

Skeletal measures of the study participants are shown in Table 4, stratified by age. BMD and BMC at LS were not significantly correlated with age, while those at TH, FN and TR were. Bone area did not clearly show an association with age. When adjusted for height and weight, BMD at TH still decreased with age (partial regression coefficient of -0.016 [SE 0.005] g/cm²/10 years [p<0.0001]), but BMD at LS increased significantly (0.042 [0.008] g/cm²/10 years [p<0.0001]). The levels of biochemical markers, such as OC, ucOC, and TRACP-5b increased with aging as well.

The prevalence rates of osteoporosis in the FORMEN participants were 3.5% at LS, 1.9% at TH, and 4.4% in at least one of LS and TH. The prevalence rates of low BMD were 26.4%, 33.9% and 41.8%, respectively. Figure 3 illustrates proportions of low BMD categories in the participants in 10-year age groupings. The proportion of men whose BMD was judged to be low only at TH showed a significant increase with increase in age (p<0.0001), while low BMD only at LS showed a decreasing trend with increasing age (p=0.0386). Diagnosis of low BMD was not well correlated with BMD at LS and TH, with a kappa coefficient of 0.45. Other skeletal measures, including diagnosis of vertebral deformities and hip geometry indices, are being analyzed and will be presented in future papers.

C. Non-skeletal measures

Physical performance tests and cognitive performance tests were carried out successfully in most participants. The database is under construction and the results will be presented in future reports. We were also successful in obtaining QOL indices.
**Discussion**

The FORMEN study is a large-scale community-based single-centre study for elderly Japanese men with comprehensive geriatric and gerontologic assessments for potential risk factors of osteoporosis and osteoporotic fractures. We have successfully conducted the baseline study as designed, and will carry out longitudinal observations for at least five years as a prospective cohort study.

The FORMEN study has some strengths compared with previous studies. First, the sample size of the FORMEN study is the largest in Japan, allowing for a high enough statistical power to evaluate risk factors of vertebral or osteoporotic fractures. Second, it has a comprehensive coverage of skeletal measures relevant to osteoporosis assessment, including vertebral deformity assessment and HSA in addition to conventional BMD measurement. Third, biochemical markers of bone turnover in sera were measured for all participants, and the remaining sera are stored at -80 °C for further measurements of newer markers. Fourth, it has comprehensive coverage of potential risk factors of osteoporosis and osteoporotic fractures based on geriatric and gerontologic assessments. Fifth, we have established highly reliable surveillance of outcome indices using official municipality databases, including onset of becoming dependent on others in daily life and mortality. Finally, a single-centre study design has an advantage over a multi-centre design with respect to quality control of study performance given that no inter-centre calibrations of study measurements are necessary.

The FORMEN study also has potential limitations. First, participants were not randomly selected, which makes generalizing the results obtained difficult. However, the Fujiwara-kyo study aims to apply the results to people living independently in the communities studied, and our results can be utilized for this purpose. Second, the sample size of the FORMEN study may still be small for assessing risk factors of hip fracture. Third, BMD measurements did not include whole body BMD or volumetric BMD obtained by quantitative computed tomography. Fourth, vertebral deformity detected with SXA images might underestimate the prevalence of vertebral fractures compared to diagnosis with conventional radiographs. Fifth, urinary levels of bone
turnover markers were not measured, although more novel serum markers were measured. Finally, the deaths of participants are confirmed, but the cause of death is not reported in the initial study protocol.

Such potential limitations of the FORMEN study may have some effects on the study results, but are not expected to invalidate the results. In turn, they may suggest some directions for future research. The study items of the FORMEN study cover most items of preceding studies, such as the Mr OS study [30]. It may be possible to combine the results with those from other studies to increase the statistical power. Extending the follow-up period of the FORMEN study is worthwhile, and can increase the power as well. New random sample studies may be desirable to generalize study results to the whole population.

Conclusions

The FORMEN study, a large-scale community-based single-centre prospective cohort study for elderly Japanese men with comprehensive coverage of potential risk factors of osteoporosis and osteoporotic fractures, designed as an ancillary study of the Fujiwara-kyo study, was successfully launched for longitudinal observations for at least five years. The study is expected to clarify a range of risk factors for osteoporotic fractures, to form predictive models of fracture risk, and to assess consequences of fractures in Japanese elderly men. These results should help health care professionals improve their preventive activities and management of osteoporosis in men.

Competing interests

None.
**Author contributions**

MI is the director of the FORMEN study, conceived of and designed the study, conducted the surveys and drafted the manuscript. YF is responsible for the FORMEN Administrative Center and conducted surveys in the study. JT participated in designing the study and conducting the surveys. YS analyzed DXA scan data to yield BMD values. KK was responsible for measurements of bone turnover markers. AY, EK and JSM were responsible for quality control of interview surveys. NO works as a secretary-general of the Administrative Center for the Fujiwara-kyo study. NK, the Principal Investigator of the Fujiwara-kyo study and the Chairperson of the Core Member Committee, conceived of and designed the Fujiwara-kyo study, and participated in designing the FORMEN study. The Fujiwara-kyo Study Group comprising Nobuko Amano, Akihiro Harano, Kan Hazaki, Junko Iwamoto, Akira Minematsu, Masayuki Morikawa, Keigo Saeki, Noriyuki Tanaka, Kimiko Tomioka and Motokazu Yanagi, in addition to the authors listed, performed the Fujiwara-kyo study and provided data for most non-skeletal study measures to the FORMEN study. All authors critically revised the manuscript and approved the final version of the manuscript for publication.

**Acknowledgements**

The authors acknowledge Eisai Co. Ltd. (Tokyo, Japan) and Sanko Junyaku Co. Ltd. (Tokyo, Japan) for their cooperation in measuring ucOC in sera, Toyukai Medical Corporation (Tokyo, Japan) and Toyo Medic Inc., (Osaka, Japan) for DXA scanning, and SRL Inc., (Tokyo, Japan) for their technical assistance in laboratory measurements. The FORMEN study was supported by several grants as follows: MI is supported by Grants-in-Aid for Scientific Research (#20659103: 2008-2009, B #21390210: 2009-2011) from the Japanese Society for the Promotion of Science, and by a Grant-in-Aid for Study on Milk Nutrition (2008) from the Japan Dairy Association. JT is supported by Grants-in-Aid for Scientific Research (C #20590661: 2008-2010) from the Japanese Society for the Promotion of Science, by a Grant (2007) from the Foundation for Total Health Promotion, and by a St. Luke’s Life Science Institute Grant-in-Aid for
Epidemiological Research (2008). YF is supported by a Grant-in-Aid for Young Scientists (B #20790451: 2008-2009) from the Japanese Society for the Promotion of Science, and by a Grant (2008) from the Physical Fitness Research Institute, MEIJI YASUDA Life Foundation of Health and Welfare. The funding bodies have never had any role in designing the study, in analyzing and interpreting the data, in writing the manuscript, or in deciding where to submit the manuscript for publication.

Figure legends

Figure 1. Study area of the Fujiwara-kyo study.

Figure 2. Time line of the Fujiwara-kyo study.

Figure 3. Proportions of BMD categories in age-stratified participants of the FORMEN baseline study, 2007-2008.

BMD: Bone mineral density
Normal: BMD greater than 1 SD below the young adult mean (YAM)
Low BMD: BMD 1 SD or more below YAM
LS: Lumbar spine
TH: Total hip
Data of 1912 subjects with BMD values available for both skeletal sites were used in the analysis.
Statistical power was estimated for a logistic regression analysis to yield a significant estimate for a risk factor with a two-tailed level of significance at 5% under a sample size of 2000 with various combinations of assumptions.

**RR:** Relative risk of fracture posed by a risk factor studied.

**PARP:** Population attributable risk proportion.

<table>
<thead>
<tr>
<th>Risk factor studied</th>
<th>Annual incidence rate of fracture (%) in population without a risk factor studied</th>
<th>PARP (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence rate (%)</td>
<td>RR</td>
<td>0.8</td>
</tr>
<tr>
<td>20</td>
<td>1.25</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>1.5</td>
<td>41</td>
</tr>
<tr>
<td></td>
<td>1.75</td>
<td>72</td>
</tr>
<tr>
<td>30</td>
<td>1.25</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>1.5</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>1.75</td>
<td>80</td>
</tr>
<tr>
<td>40</td>
<td>1.25</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>1.5</td>
<td>53</td>
</tr>
<tr>
<td></td>
<td>1.75</td>
<td>83</td>
</tr>
<tr>
<td>2</td>
<td>96</td>
<td>99</td>
</tr>
</tbody>
</table>

Statistical power was estimated for a logistic regression analysis to yield a significant estimate for a risk factor with a two-tailed level of significance at 5% under a sample size of 2000 with various combinations of assumptions.

**RR:** Relative risk of fracture posed by a risk factor studied.

**PARP:** Population attributable risk proportion.

- : Power<60%
- : 60%≤Power<80%
- : 80%≤Power

81 : Assumptions used when the present sample size of 2000 was determined.
Table 2. Age and body size between FORMEN participants and male population of Nara Prefecture or Japan.

<table>
<thead>
<tr>
<th>Index</th>
<th>Population</th>
<th>65-69 years</th>
<th>70-74 years</th>
<th>75-79 years</th>
<th>80 years and older</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age distribution</td>
<td>FORMEN study</td>
<td>627 (31.2%)</td>
<td>705 (35.0%)</td>
<td>450 (22.4%)</td>
<td>230 (11.4%)</td>
</tr>
<tr>
<td></td>
<td>Nara Prefecture&lt;sup&gt;a&lt;/sup&gt;</td>
<td>34.7%</td>
<td>28.0%</td>
<td>20.3%</td>
<td>16.9%</td>
</tr>
<tr>
<td></td>
<td>Japan&lt;sup&gt;a&lt;/sup&gt;</td>
<td>33.2%</td>
<td>28.1%</td>
<td>20.6%</td>
<td>18.1%</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>FORMEN study</td>
<td>164.8±5.9</td>
<td>163.2±5.9</td>
<td>162.7±6</td>
<td>160.5±6.4</td>
</tr>
<tr>
<td></td>
<td>Nara Prefecture&lt;sup&gt;b&lt;/sup&gt;</td>
<td>165.5±6.2</td>
<td>164.1±6.3</td>
<td>162.3±6.3</td>
<td>160.5±6.8</td>
</tr>
<tr>
<td></td>
<td>Japan&lt;sup&gt;c&lt;/sup&gt;</td>
<td>163.7±6.5</td>
<td>162.2±6.9</td>
<td>161±6.3</td>
<td>158.9±8</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>FORMEN study</td>
<td>63.3±9.1</td>
<td>62±8.6</td>
<td>60±8.6</td>
<td>56.8±8.8</td>
</tr>
<tr>
<td></td>
<td>Nara Prefecture&lt;sup&gt;b&lt;/sup&gt;</td>
<td>64.1±9.2</td>
<td>62.8±9.5</td>
<td>60.1±9.2</td>
<td>56.6±9.9</td>
</tr>
<tr>
<td></td>
<td>Japan&lt;sup&gt;c&lt;/sup&gt;</td>
<td>64.4±9.7</td>
<td>62±8.7</td>
<td>59.7±8.4</td>
<td>56±9.6</td>
</tr>
<tr>
<td>BMI (kg/m&lt;sup&gt;2&lt;/sup&gt;)</td>
<td>FORMEN study</td>
<td>23.7±3.2</td>
<td>23.7±3.1</td>
<td>23.1±3.3</td>
<td>22.4±3.3</td>
</tr>
<tr>
<td></td>
<td>Nara Prefecture&lt;sup&gt;b&lt;/sup&gt;</td>
<td>23.8±3.3</td>
<td>23.8±3.4</td>
<td>23.2±3.5</td>
<td>22.4±3.6</td>
</tr>
<tr>
<td></td>
<td>Japan&lt;sup&gt;c&lt;/sup&gt;</td>
<td>24.4±3.6</td>
<td>24±3.4</td>
<td>23.4±3.1</td>
<td>22.6±3.5</td>
</tr>
</tbody>
</table>

<sup>a</sup> Population Statistics based on the Basic Resident Registry [27]

<sup>b</sup> Annual Report of Basic Health Examinations 2007 [28]

<sup>c</sup> National Health and Nutrition Survey 2006 [29]
Table 3. Baseline characteristics of participants stratified by age in the FORMEN baseline study, 2007-2008.

<table>
<thead>
<tr>
<th>Past history and present involvement of diseases (%)</th>
<th>All age groups</th>
<th>65-69 years</th>
<th>70-74 years</th>
<th>75-79 years</th>
<th>80 years and older</th>
<th>P value a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyroid diseases</td>
<td>1.4</td>
<td>1.3</td>
<td>1.3</td>
<td>0.7</td>
<td>3.9</td>
<td>0.0915</td>
</tr>
<tr>
<td>Rheumatoid arthritis and connective tissue diseases</td>
<td>1.0</td>
<td>1</td>
<td>0.9</td>
<td>0.7</td>
<td>2.2</td>
<td>0.3419</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>10.1</td>
<td>9.4</td>
<td>10.7</td>
<td>10.9</td>
<td>8.7</td>
<td>0.9221</td>
</tr>
<tr>
<td>Asthma</td>
<td>1.2</td>
<td>1.6</td>
<td>0.7</td>
<td>1.3</td>
<td>1.3</td>
<td>0.7719</td>
</tr>
<tr>
<td>Hypertension</td>
<td>33.3</td>
<td>30.2</td>
<td>35.0</td>
<td>35.6</td>
<td>31.7</td>
<td>0.2787</td>
</tr>
<tr>
<td>Cerebrovascular diseases</td>
<td>3.7</td>
<td>2.6</td>
<td>2.8</td>
<td>6.4</td>
<td>3.9</td>
<td>0.0137</td>
</tr>
<tr>
<td>Coronary heart disease</td>
<td>4.7</td>
<td>4.3</td>
<td>4.6</td>
<td>4.9</td>
<td>5.7</td>
<td>0.4090</td>
</tr>
<tr>
<td>Malignant diseases</td>
<td>8.2</td>
<td>6.2</td>
<td>0.4</td>
<td>9.1</td>
<td>11.3</td>
<td>0.0115</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>2.4</td>
<td>1.6</td>
<td>2.1</td>
<td>3.8</td>
<td>3.0</td>
<td>0.0391</td>
</tr>
<tr>
<td>Steroid use</td>
<td>0.9</td>
<td>1.1</td>
<td>0.6</td>
<td>1.1</td>
<td>1.3</td>
<td>0.7588</td>
</tr>
<tr>
<td>Statin use</td>
<td>4.9</td>
<td>4.8</td>
<td>5.4</td>
<td>3.1</td>
<td>7.0</td>
<td>0.8217</td>
</tr>
<tr>
<td>Fragility fractures since age 50</td>
<td>4.4</td>
<td>1.2</td>
<td>4.4</td>
<td>4.9</td>
<td>4.4</td>
<td>0.7019</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lifestyle factors</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Milk consumption (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 glasses/day or more</td>
<td>8.1</td>
<td>6.2</td>
<td>8.4</td>
<td>9.1</td>
<td>10.0</td>
<td>0.0088</td>
</tr>
<tr>
<td>1 glass/day</td>
<td>43.2</td>
<td>40.4</td>
<td>43.9</td>
<td>40.4</td>
<td>53.9</td>
<td></td>
</tr>
<tr>
<td>Several glasses/week</td>
<td>15.2</td>
<td>16.6</td>
<td>15.5</td>
<td>16.2</td>
<td>8.7</td>
<td></td>
</tr>
<tr>
<td>1 glass/week or less</td>
<td>33.5</td>
<td>36.7</td>
<td>32.3</td>
<td>34.2</td>
<td>27.4</td>
<td></td>
</tr>
<tr>
<td>Smoking status (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current smokers</td>
<td>17</td>
<td>21.9</td>
<td>17.3</td>
<td>14.3</td>
<td>7.9</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Ex-smokers</td>
<td>61.4</td>
<td>56.6</td>
<td>59.8</td>
<td>65.1</td>
<td>71.9</td>
<td></td>
</tr>
</tbody>
</table>

- 22 -
<p>| | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-smokers</td>
<td>21.7</td>
<td>21.5</td>
<td>23</td>
<td>20.8</td>
<td>20.2</td>
</tr>
<tr>
<td>Number of pack-years in ever-smokers</td>
<td>41.1±</td>
<td>40.8±</td>
<td>43.2±</td>
<td>39.2±</td>
<td>39.9±</td>
</tr>
</tbody>
</table>

Alcohol drinking habit (%)

<table>
<thead>
<tr>
<th>Frequency</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than once/week</td>
<td>38.0</td>
<td>33.3</td>
<td>37.8</td>
<td>40.9</td>
<td>45.8</td>
</tr>
<tr>
<td>1-2 times/week</td>
<td>5.3</td>
<td>5.3</td>
<td>4.7</td>
<td>5.8</td>
<td>6.2</td>
</tr>
<tr>
<td>3-5 times/week</td>
<td>8.9</td>
<td>10.4</td>
<td>8.9</td>
<td>7.4</td>
<td>7.5</td>
</tr>
<tr>
<td>6 times/week or more</td>
<td>47.9</td>
<td>51.0</td>
<td>48.6</td>
<td>45.9</td>
<td>40.5</td>
</tr>
</tbody>
</table>

1 Values represent mean±SD, median with interquartile limits in parentheses, or proportion.
2 a A trend of each variable with aging was tested by a linear regression-based trend test or Cochran-Armitage trend test. Chi-squared test was applied when a variable had more than two categories.
Table 4. Skeletal measures of participants stratified by age in the FORMEN baseline study, 2007-2008.

<table>
<thead>
<tr>
<th>Index</th>
<th>All age groups</th>
<th>65-69 years</th>
<th>70-74 years</th>
<th>75-79 years</th>
<th>80 years and older</th>
<th>P for trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMD (g/cm²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LS</td>
<td>1.026±</td>
<td>1.022±</td>
<td>1.023±</td>
<td>1.03±</td>
<td>1.042±</td>
<td>0.1877</td>
</tr>
<tr>
<td></td>
<td>0.191</td>
<td>0.177</td>
<td>0.185</td>
<td>0.199</td>
<td>0.226</td>
<td></td>
</tr>
<tr>
<td>TH</td>
<td>0.878±</td>
<td>0.901±</td>
<td>0.88±</td>
<td>0.864±</td>
<td>0.841±</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td>0.126</td>
<td>0.124</td>
<td>0.121</td>
<td>0.129</td>
<td>0.13</td>
<td></td>
</tr>
<tr>
<td>FN</td>
<td>0.74±</td>
<td>0.763±</td>
<td>0.741±</td>
<td>0.72±</td>
<td>0.715±</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td>0.116</td>
<td>0.117</td>
<td>0.111</td>
<td>0.114</td>
<td>0.118</td>
<td></td>
</tr>
<tr>
<td>TR</td>
<td>0.684±</td>
<td>0.702±</td>
<td>0.685±</td>
<td>0.674±</td>
<td>0.651±</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td>0.112</td>
<td>0.109</td>
<td>0.107</td>
<td>0.117</td>
<td>0.119</td>
<td></td>
</tr>
<tr>
<td>BMC (g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.7020</td>
</tr>
<tr>
<td>LS</td>
<td>54.3±</td>
<td>54.2±</td>
<td>54.2±</td>
<td>54.5±</td>
<td>54.4±</td>
<td></td>
</tr>
<tr>
<td></td>
<td>13.3</td>
<td>12.1</td>
<td>13.4</td>
<td>14.1</td>
<td>14.4</td>
<td></td>
</tr>
<tr>
<td>TH</td>
<td>36.5±6.1</td>
<td>37.4±6.3</td>
<td>36.5±5.8</td>
<td>36±5.9</td>
<td>35.2±6.3</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>FN</td>
<td>3.9±0.6</td>
<td>4±0.6</td>
<td>3.9±0.6</td>
<td>3.8±0.6</td>
<td>3.8±0.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>TR</td>
<td>8.9±2.5</td>
<td>9.2±3.5</td>
<td>8.9±1.8</td>
<td>8.8±1.8</td>
<td>8.5±2</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Area (cm²)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LS</td>
<td>51.9±5</td>
<td>52.2±4.6</td>
<td>51.8±5.1</td>
<td>52±5.1</td>
<td>50.9±5.2</td>
<td>0.0039</td>
</tr>
<tr>
<td>TH</td>
<td>41.6±3.5</td>
<td>41.5±3.6</td>
<td>41.5±3.4</td>
<td>41.7±3.3</td>
<td>41.8±3.6</td>
<td>0.1959</td>
</tr>
<tr>
<td>FN</td>
<td>5.3±0.4</td>
<td>5.2±0.3</td>
<td>5.3±0.4</td>
<td>5.3±0.3</td>
<td>5.3±0.3</td>
<td>0.0801</td>
</tr>
<tr>
<td>TR</td>
<td>13±2</td>
<td>13.1±2.7</td>
<td>13±1.5</td>
<td>13±1.5</td>
<td>13.1±1.6</td>
<td>0.6968</td>
</tr>
</tbody>
</table>

Biochemical marker of bone turnover

| OC (ng/ml) | 4.8 (3.2, 6.5) | 4.5 (2.6, 6.1) | 4.8 (3.2, 6.5) | 5.0 (3.5, 6.8) | 5.4 (4.0, 6.9) | <0.0001 |
| ucOC (ng/ml) | 2.9 (1.5, 5.4) | 2.7 (1.5, 4.9) | 2.9 (1.6, 5.4) | 3.0 (1.6, 5.7) | 3.4 (1.8, 6.4) | <0.0001 |
| TRACP-5b (mU/dl) | 212.3 | 200.2 | 211.0 | 212.3 | 254.0 | <0.0001 |
BMD: Bone mineral density
BMC: Bone mineral content
LS: Lumbar spine  TH: Total hip  FN: Femoral neck  TR: Trochanter
OC: Osteocalcin
ucOC: Undercarboxylated osteocalcin
TRACP-5b: Tartrate resistant acid phosphatase isoenzyme 5b
Values of bone densitometric measures represent mean±SD.
OC values represent median with interquartile limits in parentheses.
ucOC and TRACP-5b values represent geometric mean with values for M-SD and M+SD in parentheses.
Bone densitometric data at the spine and at the hip were obtained from 1916 and 2008 participants, respectively, without severe deformities in the region of interest. Number of participants with available measurements for OC, ucOC and TRACP-5b were 1971, 1970 and 2003, respectively.

Additional files
none
References


9 Yoshimura N, Kasamatsu T, Sakata K, Hashimoto T, Cooper C: **The relationship between endogenous estrogen, sex hormone-binding globulin, and bone loss in female residents of a rural Japanese community: the Taiji Study.** J Bone Miner Metab 2002;20:303-10.


